A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants and Healthy Chinese and Japanese Participants

PHASE1RecruitingINTERVENTIONAL

Enrollment

138

Participants

Timeline

Start Date

September 2, 2024

Primary Completion Date

June 1, 2027

Study Completion Date

June 1, 2027

Conditions

Systemic Lupus Erythematosus

Interventions

DRUG

GSK4527363

GSK4527363 will be administered to participants.

DRUG

Placebo matching GSK4527363

Placebo matching GSK4527363 will be administered to participants.

DRUG

Belimumab

Belimumab will be administered to participants.

Trial Locations (1)

RECRUITING

GSK Investigational Site, Cambridge